Comparison of the Clinical and Laboratory Features of Patients With and Without TEL/AML1 Gene Expression (ALL-AIEOP95 and ALL-BFM95)
| . | TEL/AML1 Positive . | TEL/AML1 Negative . | ||
|---|---|---|---|---|
| . | (n = 63, 18.9%) . | (n = 271, 81.1%) . | ||
| . | . | . | . | . |
| Sex | ||||
| Male | 29 | 46% | 163 | 60% |
| Female | 34 | 54% | 108 | 40% |
| Age (yr) | ||||
| <1 | 0 | 13 | 5% | |
| 1-5 | 48 | 76% | 152 | 56% |
| 6-9 | 13 | 21% | 57 | 21% |
| 10-14 | 2 | 3% | 42 | 15% |
| 15-18 | 0 | 7 | 3% | |
| WBC | ||||
| <20,000 | 40 | 64% | 139 | 51% |
| 20-100,000 | 14 | 22% | 65 | 24% |
| ≥100,000 | 5 | 8% | 38 | 14% |
| Not known | 4 | 6% | 29 | 11% |
| Immunophenotype | ||||
| Common | 54 | 86% | 154 | 57% |
| Pre-B | 8 | 13% | 55 | 20% |
| Pre-pre-B | 1 | 1% | 8 | 3% |
| B mature | 0 | 6 | 2% | |
| T-ALL | 0 | 38 | 14% | |
| Not known | 0 | 10 | 4% | |
| DNA index | ||||
| <1 | 3 | 5% | 7 | 3% |
| 1 | 52 | 83% | 142 | 52% |
| >1 <1.16 | 0 | 38 | 14% | |
| ≥1.16 <1.6 | 2 | 3% | 46 | 17% |
| ≥1.6 | 2 | 3% | 2 | 1% |
| Not known | 4 | 6% | 36 | 13% |
| . | TEL/AML1 Positive . | TEL/AML1 Negative . | ||
|---|---|---|---|---|
| . | (n = 63, 18.9%) . | (n = 271, 81.1%) . | ||
| . | . | . | . | . |
| Sex | ||||
| Male | 29 | 46% | 163 | 60% |
| Female | 34 | 54% | 108 | 40% |
| Age (yr) | ||||
| <1 | 0 | 13 | 5% | |
| 1-5 | 48 | 76% | 152 | 56% |
| 6-9 | 13 | 21% | 57 | 21% |
| 10-14 | 2 | 3% | 42 | 15% |
| 15-18 | 0 | 7 | 3% | |
| WBC | ||||
| <20,000 | 40 | 64% | 139 | 51% |
| 20-100,000 | 14 | 22% | 65 | 24% |
| ≥100,000 | 5 | 8% | 38 | 14% |
| Not known | 4 | 6% | 29 | 11% |
| Immunophenotype | ||||
| Common | 54 | 86% | 154 | 57% |
| Pre-B | 8 | 13% | 55 | 20% |
| Pre-pre-B | 1 | 1% | 8 | 3% |
| B mature | 0 | 6 | 2% | |
| T-ALL | 0 | 38 | 14% | |
| Not known | 0 | 10 | 4% | |
| DNA index | ||||
| <1 | 3 | 5% | 7 | 3% |
| 1 | 52 | 83% | 142 | 52% |
| >1 <1.16 | 0 | 38 | 14% | |
| ≥1.16 <1.6 | 2 | 3% | 46 | 17% |
| ≥1.6 | 2 | 3% | 2 | 1% |
| Not known | 4 | 6% | 36 | 13% |